

Supporting Information For:

***In vitro* studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics**

Axel Steinbrueck,^a Adam C. Sedgwick,^a Hai-Hao Han,^{bc} Michael Y. Zhao,^a Sajal Sen,^a Dan Ying Huang,^a Yi Zang,^c Jia Li,^{c*} Xiao-Peng He^{b*} and Jonathan L. Sessler^{a*}

^aDepartment of Chemistry, The University of Texas at Austin, 105 E 24th street A5300, Austin, TX 78712-1224 (USA)

^bKey Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist Joint Research Center, School of Chemistry and Molecular Engineering, East China University of Science and Technology, 130 Meilong Rd., Shanghai 200237, China.

^cNational Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China; Email: jli@simmm.ac.cn

Emails:

yzang@simmm.ac.cn, jli@simmm.ac.cn, xphe@ecust.edu.cn, sessler@cm.utexas.edu

1. Materials, Methods and Instruments	S4
2. Synthesis	S8
2.1. Summary Scheme	S8
2.2. Deferasirox 1	S9
2.3. Methyl Ester Derivative 2	S10
2.4. Primary Amide Derivative 3	S11
2.5. Morpholine Derivative 4	S12
2.6. Triphenylphosphonium Derivative 5	S13
2.7. Quaternary Ammonium Derivative 6	S14
2.8. N-methylpiperazine Derivative 7	S15
2.9. Dimethylethylenediamine Derivative 8	S16
2.10. Ethylenediamine Derivative 9	S17
2.11. O-Methylated Dimethylethylenediamine Derivative 10	S18
2.12. Oxazinone Intermediate A	S19
2.13. N-boc-ethylenediamine Intermediate B	S20
2.14. Trimethylated Intermediate C	S21
2.15. Hydrolyzed Intermediate D	S22
3. ¹H-NMR, ¹³C-NMR and HRMS spectra; liquid chromatograms	S23
3.1. Deferasirox 1	S23
3.2. Methyl Ester Derivative 2	S25
3.3. Primary Amide Derivative 3	S27
3.4. Morpholine Derivative 4	S29
3.5. Triphenylphosphonium Derivative 5	S31
3.6. Quaternary Ammonium Derivative 6	S33
3.7. N-methylpiperazine Derivative 7	S35
3.8. Dimethylethylenediamine Derivative 8	S37
3.9. Ethylenediamine Derivative 9	S39
3.10. O-Methylated Dimethylethylenediamine Derivative 10	S41
3.11. Oxazinone Intermediate A	S43
3.12. N-boc-ethylenediamine Intermediate B	S45
3.13. Trimethylated Intermediate C	S47
3.14. Hydrolyzed Intermediate D	S49
4. Compound Stability Test	S51
5. LogD_{7.2} and logD_{4.5} Determination	S54
6. Cell Viability Studies	S55
7. UV-vis and Fluorescence Spectroscopy	S58
8. Cell Imaging	S60
9. References	S63

Common abbreviations used:

Ac	= acetyl
A549	= human lung adenocarcinoma cell line
CV	= crystal violet
DCM	= dichloromethane
DMEM	= Dulbecco's Modified Eagle Medium (cell growth medium)
DMF	= dimethylformamide
EDC*HCl	= 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
Et	= ethyl
FBS	= fetal bovine serum
logD	= distribution coefficient (with octanol and pH buffered aqueous phase)
Me	= methyl
Ms	= mesyl
MTT	= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NMR	= nuclear magnetic resonance
NHS	= N-hydroxysuccinimide
ORP	= oxidation-reduction potential
P/S	= penicillin/streptomycin
RPMI 1640	= cell growth medium
r.t.	= room temperature
TEA	= triethylamine
TFA	= trifluoroacetic acid

1. Materials, Methods and Instruments

Chemicals. All materials were obtained from commercial sources at the highest purity available and used without further purification. Reactions were carried out under air unless otherwise specified. Flash column chromatography was performed on Sorbent silica gel (40-63 μm). Analytical thin layer chromatography (TLC) analyses were carried on glass-backed silica gel plates (200 μm , Sorbent Technologies).

NMR. The reported ^1H NMR and ^{13}C NMR spectra were measured on Varian Inova spectrometers at The University of Texas at Austin using CDCl_3 and $\text{DMSO-}d_6$ as the deuterated solvents. Chemical shifts are reported relative to the residual solvent proton signals. For the spin multiplicities the following abbreviations were used: s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet), as well as appropriate combinations of these. Coupling constants for protons (J) are given in Hertz (Hz). The NMR spectra were analyzed using the software *MestReNova v.10.0.2-15465* (Mestrelab Research S.L.). All deuterated solvents were purchased from Cambridge Isotope Laboratories.

HR-MS. High-resolution electrospray ionization (ESI) mass spectra were recorded on a VG ZAB2E instrument or VG AutoSpec apparatus.

HPLC. Purity and stability verifications using HPLC were performed on an Agilent Technologies 1200 series liquid chromatography system equipped with a diode-array (UV-vis) detector and an Agilent ZORBAX Eclipse Plus C18 narrow bore column (2.1 mm internal diameter, 50 mm length, 5 micron particle size; P.N. 959746-902). The organic solvent was methanol, and the aqueous solvent was water containing 0.1% formic acid. Elution was conducted using a gradient ramp from 5% organic up to 100% organic solvent.

pH determinations. pH measurements were performed at 20°C on a calibrated Accumet® AE-150 pH meter with a glass combination pH ORP titration electrode (Ag/AgCl in sat. KCl as the internal reference) and a temperature sensor.

UV-vis spectroscopy. UV-vis spectra were taken on a Varian Cary 5000 UV-Vis-NIR Spectrophotometer. A baseline correction was performed with the corresponding blank before each spectrum was taken.

Fluorescent spectroscopy. Fluorescence spectroscopic measurements were made using an Agilent Cary Eclipse fluorescence spectrofluorometer. The emission and

excitation slit widths were fixed at 10 nm. Where applicable, respective blanks were subtracted from the spectra.

Cell culture. A549, HCT116 and L929 cells were obtained from the American Type Culture Collection (ATCC). A549 and HCT116 cells were maintained in a RPMI-1640 Medium (Sigma, St. Louis, MO, USA) and L929 cells were maintained in DMEM (Sigma, St. Louis, MO, USA). Each Medium was supplemented with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA) and 2% Penicillin/Streptomycin (P/S, Sigma, St. Louis, MO, USA) in a humidified atmosphere of 5% CO₂ and 95% air at 37°C. Cells were split when they reached 90% confluency.

HeLa cells were maintained in a Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum (Gibco, Gland Island, NY, USA) in a humidified atmosphere of 5 % CO₂ and 95 % air at 37 °C.

Cell Viability Studies. Cells were harvested and plated on a 96-well plate in 100 µL growth medium at a density of 1500 cells per well (5000 cells per well for 24 h exposure time). The cells were left to grow in an incubator at 37°C under 5% CO₂ atmosphere for 24 h. The next day, appropriate concentrations of the compound under investigation were prepared via serial dilution in growth medium and 100 µL was added per well such that each row of wells contained the same concentration of compound. Unless otherwise indicated, the highest concentration of compound was 250 µM and 3-fold serial dilution was employed. Two rows of wells were treated with only 100 µL medium as reference.

For MTT assay:

After incubation with compound for 72 h (or 24 h, respectively), 50 µL of MTT solution (3 mg/mL MTT dye in medium without FBS- and P/S) was added to each well. After an additional incubation for 3 h, the supernatant was aspirated off and 50 µL of DMSO was added to each well to solubilize the precipitated formazan dye. The optical density was measured for each well at 570 nm with an M5 microplate reader from Molecular Device, Sunnyvale, USA. From the mean absorbance of each row of well, a dose-response curve was produced which was then normalized to the wells containing untreated cells to allow for plate-to-plate comparison. The dose-response curves were subjected to non-linear regression analysis performed in Origin 2019b from Origin Labs, Inc to determine IC₅₀ and HS values. Data is shown as the mean of 3 replicate experiments and error bars represent the standard deviation.

For CV assay:

After incubation with compound for 72 h, the media was aspirated off and cells were carefully washed twice by slowly submerging the 96-well plate into a large, tap water filled dish followed by inverting the plate onto paper towel and gently tapping to remove the water without lifting of adhered cells. To each well was added 50 μ L of crystal violet solution (0.5w% in methanol/distilled water (20:80V%)) and the plate was placed into the incubator for 10 min at 37°C. The crystal violet solution was removed through inverting the plate onto paper towel and the stained cells were again carefully washed twice through slow submergence into a large, tap water filled dish followed by inverting the plate, onto paper towel and gently tapping to remove the water without lifting of stained cells. To each well was added 100 μ L ethanol to solubilize the dye. The optical density was measured for each well at 570 nm with an M5 microplate reader from Molecular Device, Sunnyvale, USA. From the mean absorbance of each row of well, a dose-response curve was produced which was then normalized to the wells containing untreated cells to allow for plate-to-plate comparison. The dose-response curves were subjected to non-linear regression analysis performed in Origin 2019b from Origin Labs, Inc to determine IC₅₀ and HS values. Data is shown as the mean of 3 replicate experiments and error bars represent the standard deviation.


Co-localization Experiments with LysoTracker Red. Cells cultured in growth medium supplemented with 10 % FBS were added to a 24-well microplate. Cells were maintained in a humidified atmosphere of 5 % CO₂ and 95 % air at 37 °C overnight. Then, cells were incubated sequentially with **2** or **8** (20 μ M), respectively, for 40 min and then LysoTracker® red (500 nM, Beyotime Biotechnology) for 30 min, and the cells on the microplate were rinsed with warm PBS and fixed with 4% paraformaldehyde for 20 min at room temperature. Immediately after sealing, the fluorescence was recorded and photographed with confocal laser scanning microscopy (Leica TCS SP8, Leica Microsystems, Wetzlar, Germany, red channel excitation at 405 nm, emission at 440–480 nm; Lyso tracker® channel excitation at 559 nm, emission at 580–620 nm).

Co-localization Experiments with Mitotracker Red. A549 cells were harvested and seeded at a density of 4×10^5 cells/dish in 35 mm dishes containing a poly-D lysine coated 10 mm glass diameter (Mat Tek P35GC-1.5- 10-C) overnight. Cells were then incubated with **5** (20 μ M) for 40 min at 37°C. Post incubation, the media was removed, and cells were washed with PBS. To the cells was added a PBS solution containing 50 nM Mitotracker® Red FM (Invitrogen™) and cells were incubated for 30 min at 37°C. After incubation, the dye PBS solution was aspirated off, the cells were washed with PBS. The cells were then imaged fluorescently on a Zeiss LSM 710 laser scanning confocal microscope using a Plan-Apo 63x/1.4 oil objective. The green channel was excited with a 405 nm laser, and the emission was detected spectrally from 482 - 555 nm. The red channel was excited with a 561 nm laser, and the emission was detected spectrally from 573 - 639 nm.

ROS visualization experiments. A549 cells were harvested and seeded at a density of 4×10^5 cells/dish in 35 mm dishes containing a poly-D lysine coated 10 mm glass diameter (Mat Tek P35GC-1.5- 10-C) overnight. Cells were then incubated at 37°C for 4 h with respective doses of compound **8** or the positive control ("Compound 1", a known redox active gold carbene complex from our lab¹). Post incubation, the media was removed, and cells were washed with PBS. To the cells was added a PBS solution containing 100 nM LysoTracker® Red DND-99 (Invitrogen™) and cells were incubated for 60 min at 37°C. After incubation, the dye PBS solution was aspirated off, the cells were washed with PBS and 2 μ M H₂DCFDA (Invitrogen™) ROS dye was added. Cells were incubated for 20 min, then the supernatant was aspirated off and replaced with fresh PBS buffer. The cells were imaged fluorescently on a Zeiss LSM 710 laser scanning confocal microscope using a Plan-Apo 63x/1.4 oil objective. The green channel was excited with a 405 nm laser, and the emission was detected spectrally from 482 - 555 nm. The red channel was excited with a 561 nm laser, and the emission was detected spectrally from 573 - 639 nm.

2. Synthesis

2.1. Summary Scheme




Scheme S1: Summary scheme for all syntheses relevant to the present study.

2.2. Deferasirox 1

4-(3,5-Bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid

This synthesis was adapted from the literature.²



In a 250 mL round bottom flask, 4-hydrazinobenzoic acid (10.5 g, 43.9 mmol) was heated at reflux in ethanol (100 mL) for 10 min. 2-(2-hydroxyphenyl)-4*H*-benzo[e][1,3]oxazin-4-one (7.40 g, 48.7 mmol, 1.1 equiv.) was added at once through a solid addition funnel and the reaction was stirred at reflux for 4 h. After cooling to room temperature, the reaction mixture was filtered off and the filter cake was washed once with cold ethanol (50 mL) and then twice with cold methanol (50 mL each). After drying under vacuum, the product was obtained as a pale brown powder (12.5 g, 33.5 mmol, 76%).

For biological studies, a portion of the product (5.0 g, 13 mmol) was recrystallized from ethanol (400 mL) to produce a white fluffy powder (2.9 g, 10 mmol, 58%).

¹H-NMR (500 MHz, DMSO-*d*₆):

δ 13.09 (s, 1 H, COO-*H*), 10.81 (s, 1 H, O-*H*), 10.06 (s, 1 H, O-*H*), 8.06 (dd, *J* = 1.7, 7.8 Hz, 1 H, Ar*H*), 7.98-8.01 (m, 2 H, Ar*H*), 7.53 - 7.58 (m, 3 H, Ar*H*), 7.35 - 7.42 (m, 2 H, Ar*H*), 6.96 - 7.05 (m, 3 H, Ar*H*), 6.87 (dd, *J* = 1.0, 8.3 Hz, 1 H, Ar*H*)

¹³C-NMR (125.75 MHz, DMSO-*d*₆):

δ 166.9, 160.4, 156.8, 155.6, 152.5, 141.7, 133.0, 131.9, 131.5, 131.0, 130.8, 127.2, 123.8, 120.2, 119.9, 117.5, 116.6, 114.9, 114.1


HR-MS (ESI): C₂₁H₁₅N₃O₄

Calculated ([M+H]⁺): 374.1141

Found: 374.1143

2.3. Methyl Ester Derivative 2

Methyl 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoate



To a 250 mL round bottom flask equipped with a reflux condenser was added 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (3.0 g, 8.04 mmol), methanol (200 mL) and methanesulfonic acid (1 mL). The reaction was stirred for 72 h under reflux while the reaction progress was monitored via TLC every 24 h (hexanes: ethyl acetate (75:25 V/V)). Once the reaction was deemed complete, the volatiles were removed under reduced pressure and the residue was taken up in DCM (100 mL). The organic layer was extracted twice with saturated aqueous sodium bicarbonate (100 mL per extraction), and once more with water (100 mL). The organic layer was concentrated and purified via column chromatography on silica gel (hexanes: ethyl acetate (75:25 V/V)). After drying under vacuum, the product was obtained as a white powder (2.7 g, 6.9 mmol, 87%).

¹H-NMR (500 MHz, DMSO-*d*₆):

δ 10.79 (s, 1 H, O-*H*), 10.04 (s, 1 H, O-*H*), 8.05 (d, *J* = 7.8 Hz, 1 H, Ar*H*), 8.01 (d, *J* = 8.5 Hz, 2 H, Ar*H*), 7.59 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.56 (d, *J* = 8.1 Hz, 1 H, Ar*H*), 7.35 - 7.43 (m, 2 H, Ar*H*), 6.96 - 7.05 (m, 3 H, Ar*H*), 6.86 (d, *J* = 8.3 Hz, 1 H, Ar*H*)

¹³C-NMR (125.75 MHz, DMSO-*d*₆):

δ 165.4, 159.9, 156.3, 155.1, 152.1, 141.5, 132.6, 131.5, 131.1, 130.2, 129.3, 126.8, 123.4, 119.7, 119.5, 117.1, 116.1, 114.4, 113.6, 52.4

HR-MS (ESI): C₂₂H₁₇N₃O₄


Calculated ([M+H]⁺): 388.1297

Found: 388.1299

2.4. Primary Amide Derivative 3

4-(3,5-Bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzamide

This synthesis was adapted from the literature.³



In a mortar, 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (300 mg, 0.8 mmol, 1.0 equiv.), imidazole (110 mg, 1.6 mmol, 2.0 equiv.) and urea (190 mg, 3.2 mmol, 4.0 equiv.) were ground to a fine powder. The mixture was transferred into a 10 mL microwave tube and allowed to react in a microwave reactor (CEM Discover S-Series, 150 W, 170°C, 20 min). The crude mixture obtained in this way was taken up in ethyl acetate (50 mL) and filtered. The filter cake was washed with ethyl acetate (3 times, 50 mL each). The combined filtrate was transferred into a separatory funnel, washed two times with saturated sodium bicarbonate (150 mL each) and once with brine (100 mL) and then dried over magnesium sulfate. After filtration and concentration under reduced pressure, the crude product was purified via flash column chromatography on silica gel (DCM: ethyl acetate (75:25 V/V)) to yield the product as a white powder (220 mg, 74%).

¹H-NMR (500 MHz, DMSO-*d*₆):

δ 10.81 (s, 1 H, O-*H*), 10.07 (s, 1 H, O-*H*), 8.01 – 8.09 (m, 2 H, 1 Ar*H*, 1 CON-*H*), 7.92 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.45 - 7.55 (m, 4 H, 3 Ar*H*, 1 CON-*H*), 7.34 - 7.42 (m, 2 H, Ar*H*), 6.95 - 7.05 (m, 3 H, Ar*H*), 6.87 (d, *J* = 8.3 Hz, 1 H, Ar*H*)

¹³C-NMR (125.75 MHz, DMSO-*d*₆):

δ 166.8, 159.8, 156.3, 155.3, 152.0, 139.9, 134.1, 132.5, 131.5, 131.1, 128.4, 126.8, 123.1, 119.7, 119.4, 117.1, 116.1, 114.5, 113.7


HR-MS (ESI): C₂₁H₁₆N₄O₃

Calculated ([M+H]⁺): 373.1295

Found: 373.1306

2.5. Morpholine Derivative 4

(4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)phenyl)(morpholino)methanone



In a 100 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC•HCl, 770 mg, 4.0 mmol), 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid (1.0 g, 2.7 mmol), triethylamine (0.6 mL, 4.0 mmol) and NHS (10 mg, catalyst) were dissolved in DCM (30 mL) and stirred at r.t. for 5 min. Morpholine (0.35 mL, 4.0 mmol) was added and the reaction was stirred at r.t. overnight for 16 h. The solvent was removed under reduced pressure, yielding a pale white-brown solid that was taken up in ethyl acetate (100 mL) and extracted three times with water (100 mL). The aqueous layers were combined and back-extracted once with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography on silica gel (ethyl acetate: hexanes (50: 50 V/V)) to yield the product as a white powder (0.62 g, 1.4 mmol, 52%).

¹H-NMR (500 MHz, CDCl₃):

δ 11.39 (s, 1 H, O-H), 9.59 (s, 1 H, O-H), 8.14 (dd, *J* = 1.7, 7.8 Hz, 1 H, ArH), 7.57 – 7.65 (m, 4 H, ArH), 7.32 – 7.42 (m, 2 H, ArH), 7.14 (dd, *J* = 1.2, 8.4 Hz, 1 H, ArH), 7.02 – 7.10 (m, 2 H, ArH), 6.99 (dd, *J* = 1.6, 8.0 Hz, 1 H, ArH), 6.69 (ddd, *J* = 1.2, 7.3, 8.2 Hz, 1 H, ArH), 3.36 – 4.00 (m, 8 H, -CH₂-)

¹³C-NMR (125.75 MHz, CDCl₃, 65°C):

δ 169.0, 160.0, 158.4, 156.9, 152.6, 139.6, 137.5, 133.2, 132.0, 129.0, 127.9, 127.8, 126.6, 120.1, 119.3, 118.7, 117.4, 113.6, 110.4, 67.1, 45.5 (broad)*


*splits into a doublet at r.t. δ 45.5, *J* = 699 Hz, 2 C, -CH₂-

HR-MS (ESI): C₂₅H₂₂N₄O₄

Calculated ([M+H]⁺): 443.1714

Found: 443.1714

2.6. Triphenylphosphonium Derivative 5
(2-(4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzamido)ethyl)triphenylphosphonium



In a 250 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC·HCl, 0.77 g, 4.0 mmol), 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid (1.0 g, 2.7 mmol), triethylamine (TEA, 0.5 mL, 4.0 mmol) and N-hydroxysuccinimide (NHS, 10 mg, catalyst) were dissolved in DCM (20 mL) and stirred for 5 min at r.t. (2-Aminoethyl)triphenylphosphonium bromide (1.2 g, 3.2 mmol) was added and the reaction mixture was stirred for 16 h at r.t. Once the reaction was deemed complete, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The viscous residue was taken up in DCM (50 mL), loaded onto a silica gel column and purified via flash chromatography (gradient elution 95:05 DCM: methanol with 0.1% AcOH to 60:40 DCM: methanol with 1% AcOH) to yield the product as a brown powder (1.02 g, 45%).

^1H -NMR (500 MHz, CDCl_3):

δ 10.13 (s, 1 H, N-H), 8.12 (d, J = 8.1 Hz, 1 H, ArH), 7.98 (d, J = 7.9 Hz, 2 H, ArH), 7.68 - 7.78 (m, 9 H, ArH), 7.57 - 7.63 (m, 6 H, ArH), 7.43 (d, J = 8.0 Hz, 2 H, ArH), 7.32 (t, J = 7.6 Hz, 1 H, ArH), 7.26 (t, J = 7.6 Hz, 1 H, ArH), 7.18 (d, J = 9.4 Hz, 1 H, ArH), 7.04 (t, J = 8.2 Hz, 2 H, ArH), 6.97 (t, J = 7.7 Hz, 1 H, ArH), 6.76 (t, J = 7.7 Hz, 1 H, ArH), 3.83 (s, 4 H, $-\text{CH}_2-$), 1.83 (s, 3 H, CH_3COO^- , counter anion)

^{13}C -NMR (125.75 MHz, CDCl_3):

δ 177.4, 167.1, 160.0, 157.4, 156.9, 152.5, 140.6, 135.2, 134.3, 133.7, 133.6, 132.7, 131.4, 130.6, 130.5, 129.3, 129.2, 127.4, 124.5, 119.7, 119.1, 118.4, 117.8, 117.7, 117.2, 113.9, 112.6, 34.11, 31.06, 23.74, 22.6, 22.2


$\text{C}_{41}\text{H}_{34}\text{N}_4\text{O}_3\text{P}^+$

Calculated ($[\text{M}]^+$): 661.2363

Found: 661.2359

2.7. Quaternary Ammonium Derivative 6

2-(4-(3,5-Bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzamido)-*N,N,N*-trimethylethan-1-aminium hexafluorophosphate



In a 250 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC·HCl, 1.0 g, 5.4 mmol), 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (1.0 g, 2.7 mmol), triethylamine (TEA, 0.8 mL, 5.4 mmol) and *N*-hydroxysuccinimide (NHS, 10 mg, catalyst) were dissolved in DCM (40 mL) and stirred for 5 min at r.t. (2-Aminoethyl)trimethylammonium chloride hydrochloride (1.0 g, 5.7 mmol) was added and the reaction mixture was stirred for 16 h at r.t. Upon completion, the solvent was removed under reduced pressure and the residual pale white-brown solid was taken up in methanol (10 mL) due to limited solubility in other solvents. The crude product was purified via flash chromatography on silica gel (90:10 DCM: methanol to remove impurities, then 25:50:25 ethyl acetate: isopropyl alcohol: water to elute the product) to yield moderately pure product as an orange solid. This solid was taken up in the minimum amount of methanol needed to dissolve it fully (≈ 3 mL). Aqueous ammonium hexafluorophosphate (10 equiv. in 10 mL water) was added until the product precipitated as white powder (230 mg, 0.5 mmol 19%).

$^1\text{H-NMR}$ (500 MHz, DMSO- d_6):

δ 10.81 (s, 1 H, O-*H*), 9.84 (s, 1 H, CON-*H*), 8.04 (dd, $J = 1.5, 7.8$ Hz, 1 H, Ar*H*), 7.90 (d, $J = 8.3$ Hz, 2 H, Ar*H*), 7.57 (d, $J = 8.5$ Hz, 2 H, Ar*H*), 7.51 (d, $J = 7.8$ Hz, 1 H, Ar*H*), 7.38 (td, $J = 1.5, 7.0$ Hz, 2 H, Ar*H*), 6.99 - 7.05 (m, 2 H, Ar*H*), 6.95 (d, $J = 7.4$ Hz, 1 H, Ar*H*), 6.86 (d, $J = 7.6$ Hz, 1 H, Ar*H*), 3.69 (d, $J = 5.4$ Hz, 2 H, CH₂), 3.69 (d, $J = 6.5$ Hz, 2 H, CH₂), 3.13 (s, 3 H, CH₃)

$^{13}\text{C-NMR}$ (125.75 MHz, DMSO- d_6):

δ 165.7, 159.8, 156.3, 152.1, 140.1, 133.5, 132.4, 131.5, 131.0, 128.2, 126.7, 123.4, 119.7, 117.1, 116.2, 114.5, 113.7, 69.8, 63.8, 52.6, 33.8


HR-MS (ESI): C₂₆H₂₇N₅O₃

Calculated ([M+H]⁺): 458.2187

Found: 458.2195

2.8. N-methylpiperazine Derivative 7

(4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)phenyl)(4-methylpiperazin-1-yl)methanone



In a 100 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC•HCl, 770 mg, 4.0 mmol), 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid (1.0 g, 2.7 mmol), triethylamine (0.6 mL, 4.0 mmol) and NHS (10 mg, catalyst) were dissolved in DCM (30 mL) and stirred at r.t. for 5 min. N-methylpiperazine (0.45 mL, 4.0 mmol) was added and the reaction was stirred at r.t. overnight for 16 h. The volatiles were removed under reduced pressure, yielding a pale white-brown solid that was taken up in ethyl acetate (100 mL) and extracted three times with water (100 mL). The aqueous layers were combined and back-extracted once with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography on silica gel (ethyl acetate: hexanes (50: 50 V/V)) to yield the product as a white powder (0.58 g, 1.3 mmol, 49%).

¹H-NMR (500 MHz, CDCl₃):

δ 11.30 (s, 1 H, O-H), 9.56 (s, 1 H, O-H), 8.06 (d, *J* = 10.4 Hz, 1 H, ArH), 7.48 – 7.55 (m, 4 H, ArH), 7.25 – 7.33 (m, 2 H, ArH), 7.12 (d, *J* = 8.4 Hz, 1 H, ArH), 6.98 – 7.10 (m, 3 H, ArH), 6.67 – 6.71 (m, 1 H, ArH), 3.85 (broad s, 2 H, -CH₂-), 3.50 (broad s, 2 H, -CH₂-), 2.53 (broad s, 2 H, -CH₂-), 2.41 (broad s, 2 H, -CH₂-), 2.35 (s, 3 H, -CH₃)

¹³C-NMR (125.75 MHz, CDCl₃, r.t.):

δ 168.9, 159.6, 158.1, 156.6, 152.3, 139.2, 137.6, 133.2, 132.0, 128.9, 127.8, 126.4, 120.1, 119.3, 118.5, 117.3, 113.4, 110.1, 55.4*, 54.8*, 47.9*, 46.1, 42.4*

*the 4 -CH₂- protons from the piperazine ring produce 4 distinct peaks at r.t., similar to the -CH₂- protons in **4** (morpholine derivative) discussed above


HR-MS (ESI): C₂₆H₂₅N₅O₃

Calculated ([M+H]⁺): 456.2030

Found: 456.2037

2.9. Dimethylethylenediamine Derivative 8

4-(3,5-Bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)-*N*-(2-(dimethylamino)ethyl)benzamide



In a 250 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC·HCl, 1.0 g, 5.4 mmol), 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (1.0 g, 2.7 mmol), triethylamine (TEA, 0.8 mL, 5.4 mmol) and *N*-hydroxysuccinimide (NHS, 10 mg, catalyst) were dissolved in DCM (40 mL) and stirred for 5 min at r.t. *N,N*-Dimethylethane-1,2-diamine (0.9 mL, 8.0 mmol) was added and the reaction mixture was stirred for 16 h at r.t. Once the reaction was deemed complete, the volatiles were removed under reduced pressure and the residual pale white-brown solid was taken up in ethyl acetate (100 mL) and extracted three times with water (100 mL each). The aqueous layers were combined and back-extracted once with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography on silica gel (95:05 DCM: methanol) to yield the product as a white powder (0.24 g, 0.6 mmol, 23%).

¹H-NMR (500 MHz, CDCl₃):

δ 8.12 (dd, *J* = 1.7, 7.8 Hz, 1 H, Ar*H*), 7.98 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.57 (d, *J* = 8.5 Hz, 2 H, Ar*H*), 7.31 – 7.39 (m, 2 H, Ar*H*), 7.17 (broad s, 1 H, N-*H*), 7.10 (dd, *J* = 1.2, 8.4 Hz, 1 H, Ar*H*), 7.06 (dd, *J* = 1.1, 8.3 Hz, 1 H, Ar*H*), 7.02 (td, *J* = 1.1, 7.6 Hz, 1 H, Ar*H*), 6.97 (dd, *J* = 1.6, 8.0 Hz, 1 H, Ar*H*), 6.65 – 6.70 (m, 1 H, Ar*H*), 3.57 (q, *J* = 5.5 Hz, 2 H, -CH₂-), 2.60 (t, *J* = 5.9 Hz, 2 H, -CH₂-), 2.33 (s, 6 H, -CH₃)

¹³C-NMR (125.75 MHz, CDCl₃):

δ 166.2, 159.7, 158.0, 156.7, 152.2, 140.5, 136.0, 133.1, 131.9, 128.9, 128.0, 127.7, 126.1, 120.0, 119.3, 118.4, 117.3, 113.4, 110.5, 57.8, 45.2, 37.3

HR-MS (ESI⁺): C₂₅H₂₅N₅O₃

Calculated ([M+H]⁺): 444.2030

Found: 444.2035

2.10. Ethylenediamine Derivative 9

***N*-(2-Aminoethyl)-4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzamide**



In a 250 mL round bottom flask, *tert*-butyl (2-(4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzamido)ethyl)carbamate (250 mg, 0.5 mmol), trifluoroacetic acid (TFA, 15 mL) and dichloromethane (20 mL) were stirred at r.t. overnight for 16 h. The volatiles were removed under reduced pressure to give a viscous, brown liquid that slowly solidified under vacuum to yield the TFA salt of the product as a crystalline pale-brown solid (250 mg, 97%).

¹H-NMR (500 MHz, DMSO-*d*₆):

δ 8.70 (t, *J* = 5.3 Hz, CON-*H*) 8.05 (d, *J* = 7.8 Hz, 1 H, Ar*H*), 7.92 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.84 (broad s, 3 H, -NH₃⁺), 7.55 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.51 (d, *J* = 7.4 Hz, 1 H, Ar*H*), 7.38 (q, *J* = 7.4 Hz, 2 H, Ar*H*), 6.94 – 7.05 (m, 3 H, Ar*H*), 3.50 (q, *J* = 5.7 Hz, 2 H, -CH₂-), 2.99 (q, *J* = 5.7 Hz, 2 H, -CH₂-)

¹³C-NMR (125.75 MHz, DMSO-*d*₆):


δ 165.9, 159.8, 158.5 (q, CF₃), 156.4, 155.4, 152.0, 140.0, 133.9, 132.5, 131.5, 131.1, 128.4, 126.8, 123.3, 119.7, 119.4, 117.1, 116.2, 114.5, 113.7, 38.7, 37.2

HR-MS (ESI): C₂₁H₁₅N₃O₄

Calculated ([M+H]⁺): 416.1717

Found: 416.1728

2.11. *O*-Methylated Dimethylethylenediamine Derivative **10**
4-(3,5-Bis(2-methoxyphenyl)-1*H*-1,2,4-triazol-1-yl)-*N*-(2-(dimethylamino)ethyl)benzamide



In a 250 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC·HCl, 400 mg, 2.1 mmol), 4-(3,5-bis(2-methoxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (500 mg, 1.2 mmol), triethylamine (0.3 mL, 2.1 mmol) and NHS (10 mg, catalyst) were dissolved in DCM (20 mL) and stirred at r.t. for 5 min. *N,N*-Dimethylethyane-1,2-diamine (0.5 mL, 4.5 mmol) was added and the reaction was stirred at r.t. for 16 h. The volatiles were removed under reduced pressure, yielding a pale white-brown solid that was taken up in ethyl acetate (100 mL) and extracted three times with water (100 mL per extraction). The aqueous layers were combined and back-extracted once with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography on silica gel (95:05 dichloromethane: methanol) to yield the product as a white powder (110 mg, 0.2 mmol, 19%).

¹H-NMR (500 MHz, CDCl₃):

δ 8.04 (d, *J* = 7.5, 1 H, Ar*H*), 7.92 (d, *J* = 8.4, 2 H, Ar*H*), 7.79 (s, 1 H, Ar*H*), 7.66 (d, *J* = 7.5, 1 H, Ar*H*), 7.38 - 7.48 (m, 4 H, Ar*H*), 7.02 - 7.10 (m, 3 H, Ar*H*), 6.81 (d, *J* = 8.4, 1 H, Ar*H*), 3.95 (s, 3 H, -CH₃), 3.69 (q, *J* = 5.4, 2 H, -CH₂-), 3.33 (s, 3 H, -CH₃), 2.88 (t, *J* = 5.6, 2 H, -CH₂-), 2.56 (s, 6 H, -CH₃)

¹³C-NMR (125.75 MHz, CDCl₃):

δ 166.7, 160.8, 157.8, 156.8, 152.2, 141.8, 132.8, 132.2, 131.7, 131.4, 130.7, 128.2, 123.1, 121.2, 120.7, 120.1, 118.0, 111.9, 111.5, 58.5, 56.2, 55.0, 44.7, 36.3, 29.4

HR-MS (ESI): C₂₇H₂₉N₅O₃


Calculated ([M+H]⁺): 472.2343

Found: 472.2348

2.12. Oxazinone Intermediate A

2-(2-Hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one

This synthesis was adapted from the literature.²



In a 250 ml round bottom flask equipped with a reflux condenser, salicylic acid (11.1 g, 80.2 mmol, 1.1 eq), salicylamide (10.0 g, 72.9 mmol, 1.0 eq) and pyridine (0.5 ml, catalyst) were dissolved in *o*-xylene (50 ml) and the solution was heated to 80°C. SOCl₂ (5.0 ml, 69.3 mmol 0.9 eq) was added dropwise over the course of 5 min. The reaction mixture was heated further to 120°C, stirred for 1 h, and then another aliquot of SOCl₂ (5.0 ml, 69.3 mmol 0.9 eq) was added dropwise over the course of 5 min. The reaction was stirred for another 1 h at 120°C. After cooling, the volatiles were removed from the reaction mixture under reduced pressure and to the residue was added ethanol (50 mL) and acetic acid (1 mL). The resulting suspension was cooled to 4°C in a refrigerator for 10 min and the precipitate was filtered off, washed with cold ethanol (three times, 50 mL each) and dried under vacuum to yield the product as a yellow-green powder (17.9 g, 93%).

¹H-NMR (400 MHz, CDCl₃):

δ 12.73 (s, 1 H, O-H), 8.22 (dd, *J* = 1.7, 8.2 Hz, 1 H, ArH), 8.12 (ddd, *J* = 0.4, 1.7, 8.1 Hz, 1 H, ArH), 7.81 (ddd, *J* = 1.7, 7.4, 8.4 Hz, 1 H, ArH), 7.51-7.57 (m, 3 H, ArH), 7.10 (ddd, *J* = 0.4, 1.2, 8.5 Hz, 1 H, ArH), 7.01 (ddd, *J* = 1.2, 7.1, 8.2 Hz, 1 H, ArH)

¹³C-NMR (100.6 MHz, CDCl₃):

δ 165.3, 164.0, 163.2, 154.2, 136.9, 135.8, 128.7, 128.1, 127.3, 119.5, 118.9, 118.4, 117.0, 111.3


HR-MS (ESI): C₁₄H₉NO₃

Calculated ([M+H]⁺): 240.0661

Found: 240.0658

2.13. *N*-*boc*-ethylenediamine Intermediate **B**

***tert*-Butyl (2-(4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzamido)ethyl)carbamate**



In a 250 mL round bottom flask, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (EDC•HCl, 2.03 g, 10.6 mmol, 1.1 equiv.) and 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (3.60 g, 9.6 mmol, 1.0 equiv.) were dissolved in DCM (50 mL) and stirred at r.t. for 5 min. *N*-*Boc*-ethylenediamine (1.5 g, 1.5 mL, 9.6 mmol, 1.0 equiv.) was added and the reaction was stirred at r.t. overnight for 16 h. The solvent was removed under reduced pressure, yielding a pale white-brown solid that was taken up in ethyl acetate (100 mL) and extracted three times with water (100 mL each). The aqueous layers were combined and back-extracted once with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography on silica gel (hexanes: ethyl acetate (40:60 V/V to 80:20 V/V)) to yield the product as a white powder (2.80 g, 5.4 mmol, 56%).

^1H -NMR (400 MHz, CDCl_3):

δ 8.12 (dd, $J = 1.7, 7.9$ Hz, 1 H, ArH), 8.03 (d, $J = 8.5$ Hz, 2 H, ArH), 7.63 (broad s, 1 H, CON-H), 7.57 (d, $J = 8.5$ Hz, 2 H, ArH), 7.30 – 7.40 (m, 2 H, ArH), 7.14 (d, $J = 8.3$ Hz, 1 H, ArH), 7.07 (d, $J = 8.4$ Hz, 1 H, ArH), 7.03 (t, $J = 7.5$ Hz, 1 H, ArH), 6.90 (dd, $J = 1.5, 8.0$ Hz, 1 H, ArH), 6.64 (dd, $J = 7.0, 8.4$ Hz, 1 H, ArH), 5.02 (broad s, 1 H, CON-H), 3.56 – 3.62 (m, 2 H, $-\text{CH}_2-$), 3.41 – 3.47 (m, 2 H, $-\text{CH}_2-$), 1.42 (s, 1 H, $-\text{CH}_3$)

^{13}C -NMR (100.6 MHz, CDCl_3):

δ 161.2, 159.5, 158.2, 156.7, 152.2, 140.5, 135.9, 133.2, 132.0, 129.0, 127.8, 127.7, 126.4, 120.1, 119.2, 118.6, 117.3, 113.3, 110.0, 80.6, 43.2, 39.9, 28.5


HR-MS (ESI): $\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$

Calculated ($[\text{M}-\text{H}]^-$): 514.2096

Found: 514.2095

2.14. Trimethylated Intermediate C

Methyl 4-(3,5-bis(2-methoxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoate



In a 100 mL round bottom flask, 4-(3,5-bis(2-hydroxyphenyl)-1*H*-1,2,4-triazol-1-yl)benzoic acid (2.0 g, 5.4 mmol) and potassium carbonate (4.4 g, 32 mmol) were dissolved in DMF (20 mL) at r.t. Via a syringe, methyl iodide (4.0 mL, 64 mmol) was added and the reaction mixture was stirred for 48 h. Then, the solvent was removed under reduced pressure and the residue taken up in DCM (50 mL) and filtered. The filter cake was washed three times with DCM (50 mL per washing) and the filtrate concentrated under reduced pressure. The crude product was purified via column chromatography on silica gel (increasing gradient: hexanes: ethyl acetate (80:20 V/V to 50:50 V/V)). After drying under vacuum, the product was obtained as a pale-yellow powder (1.4 g, 63%).

¹H-NMR (500 MHz, CDCl₃):

δ 8.03-8.07 (m, 1 H, ArH), 7.98-8.02 (m, 2 H, ArH), 7.68-7.71 (m, 1 H, ArH), 7.37 - 7.48 (m, 4 H, ArH), 7.02-7.12 (m, 3 H, ArH), 7.16 (dd, 1 H, *J* = 1.2, 8.4 Hz, ArH), 6.80 (d, *J* = 8.3 Hz, 1 H, ArH), 3.96 (s, 3 H, OCH₃), 3.90 (s, 3 H, OCH₃), 3.30 (s, 3 H, OCH₃)

¹³C-NMR (125.75 MHz, CDCl₃):

δ 166.4, 160.9, 157.7, 156.6, 152.3, 142.8, 132.3, 131.7, 131.3, 130.8, 130.4, 129.1, 122.8, 121.2, 120.7, 119.9, 118.0, 111.8, 111.4, 56.2, 54.9, 52.4


HR-MS (ESI): C₂₄H₂₁N₃O₄

Calculated ([M+H]⁺): 416.1605

Found: 416.1606

2.15. Hydrolyzed Intermediate D

4-(3,5-Bis(2-methoxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid



In a 250 mL round bottom flask, methyl 4-(3,5-bis(2-methoxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate (2.0 g, 4.8 mmol), aqueous sodium hydroxide (1 N, 20 mL) and methanol (20 mL) were stirred for 72 h at 40°C. After the reaction was cooled to r.t., the volatiles were removed under reduced pressure and the aqueous liquor was acidified with aqueous hydrochloric acid (1 N) until a bulky white precipitate had formed. The suspension was filtered, and the filter cake washed three times with water (50 mL each washing). The filter cake was dried under vacuum to yield the product as a white powder (1.76 g, 91%).

¹H-NMR (500 MHz, DMSO-*d*₆):

δ 7.98 (d, *J* = 8.3 Hz, 2 H, ArH), 7.86 (d, *J* = 8.2 Hz, 1 H, ArH), 7.64 (d, *J* = 8.2 Hz, 1 H, ArH), 7.55 (t, *J* = 8.4 Hz, 1 H, ArH), 7.47 (t, *J* = 8.0 Hz, 1 H, ArH), 7.43 (d, *J* = 8.3 Hz, 2 H, ArH), 7.19 (d, *J* = 8.4 Hz, 1 H, ArH), 7.15 (t, *J* = 7.5 Hz, 1 H, ArH), 7.09 (t, *J* = 8.0 Hz, 1 H, ArH), 7.05 (d, *J* = 8.4 Hz, 1 H, ArH), 3.86 (s, 3 H, OCH₃), 3.30 (s, 3 H, OCH₃)

¹³C-NMR (125.75 MHz, CDCl₃):

δ 166.5, 159.9, 157.3, 156.1, 151.7, 141.7, 132.4, 131.2, 130.9, 130.6, 130.2, 130.1, 122.8, 121.0, 120.3, 119.6, 117.3, 112.3, 111.9, 55.7, 54.9



HR-MS (ESI): C₂₃H₁₉N₃O₄

Calculated ([M+H]⁺): 402.1448


Found: 402.1450

3. ^1H -NMR, ^{13}C -NMR and HRMS Spectra; Liquid Chromatograms


3.1. Deferasirox **1**




HPLC trace of **1** monitored at 240 nm



^1H -NMR spectrum of **1** (400 MHz, $\text{DMSO}-d_6$)



^{13}C -NMR spectrum of **1** (100.6 MHz, $\text{DMSO}-d_6$)





Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
374.1143	374.1135	1	983483	$\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$	$(\text{M}+\text{H})^+$	-2.06
375.1173	375.1166	1	236734	$\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$	$(\text{M}+\text{H})^+$	-1.68
376.1198	376.1193	1	36037	$\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$	$(\text{M}+\text{H})^+$	-1.28
377.1243	377.1218	1	3565	$\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$	$(\text{M}+\text{H})^+$	-6.62
378.0973	378.1244	1	720	$\text{C}_{21}\text{H}_{15}\text{N}_3\text{O}_4$	$(\text{M}+\text{H})^+$	71.53


--- End Of Report ---

HRMS (ESI) analysis of **1**


3.2. Methyl Ester Derivative **2**




HPLC trace of **2** monitored at 240 nm



^1H -NMR spectrum of **2** (500 MHz, $\text{DMSO}-d_6$)



^{13}C -NMR spectrum of **2** (125.75 MHz, $\text{DMSO}-d_6$)




Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
388.1299	388.1292	1	506091	C ₂₂ H ₁₇ N ₃ O ₄	(M+H) ⁺	-1.82
389.1329	389.1323	1	121523	C ₂₂ H ₁₇ N ₃ O ₄	(M+H) ⁺	-1.52
390.1351	390.1350	1	18362	C ₂₂ H ₁₇ N ₃ O ₄	(M+H) ⁺	-0.34
391.1447	391.1376	1	2392	C ₂₂ H ₁₇ N ₃ O ₄	(M+H) ⁺	-18.26


--- End Of Report ---

HRMS (ESI) analysis of **2**


3.3. Primary Amide Derivative **3**




HPLC trace of **3** monitored at 240 nm



^1H -NMR spectrum of **3** (500 MHz, $\text{DMSO}-d_6$)



¹³C-NMR spectrum of **3** (125.75 MHz, DMSO-*d*₆)





Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
373.1306	373.1295	1	905134	C ₂₁ H ₁₆ N ₄ O ₃	(M+H) ⁺	-2.83
374.1328	374.1325	1	220676	C ₂₁ H ₁₆ N ₄ O ₃	(M+H) ⁺	-0.62
375.1352	375.1352	1	31259	C ₂₁ H ₁₆ N ₄ O ₃	(M+H) ⁺	-0.08
376.1375	376.1378	1	3194	C ₂₁ H ₁₆ N ₄ O ₃	(M+H) ⁺	0.79


--- End Of Report ---

HRMS (ESI) analysis of **3**


3.4. Morpholine Derivative 4




HPLC trace of **4** monitored at 240 nm



^1H -NMR spectrum of **4** (500 MHz, CDCl_3)



^{13}C -NMR spectrum of **4** (125.75 MHz, CDCl_3)





Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
443.1714	443.1714	1	368624	C ₂₅ H ₂₂ N ₄ O ₄	(M+H) ⁺	-0.01
444.1739	444.1744	1	102880	C ₂₅ H ₂₂ N ₄ O ₄	(M+H) ⁺	1.16
445.1760	445.1772	1	17206	C ₂₅ H ₂₂ N ₄ O ₄	(M+H) ⁺	2.75
446.1790	446.1798	1	2307	C ₂₅ H ₂₂ N ₄ O ₄	(M+H) ⁺	1.89
447.1652	447.1624	1	475	C ₂₅ H ₂₂ N ₄ O ₄	(M+H) ⁺	38.44


--- End Of Report ---

HRMS (ESI) analysis of **4**


3.5. Triphenylphosphonium Derivative **5**




HPLC trace of **5** monitored at 240 nm



^1H -NMR spectrum of **5** (500 MHz, CDCl_3)



¹³C-NMR spectrum of 5 (125.75 MHz, CDCl₃)





Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
458.2195	458.2187	1	6397503	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-1.84
459.2227	459.2217	1	1967543	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.23
460.2256	460.2245	1	343212	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.41
461.2270	461.2271	1	35026	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	0.31
462.2307	462.2297	1	3280	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.07


--- End Of Report ---

HRMS (ESI) analysis of 5


3.6. Quaternary Ammonium Derivative **6**




HPLC trace of **6** monitored at 240 nm



^1H -NMR spectrum of **6** (500 MHz, $\text{DMSO}-d_6$)



¹³C-NMR spectrum of **6** (125.75 MHz, DMSO-*d*₆)







Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
458.2195	458.2187	1	6397503	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-1.84
459.2227	459.2217	1	1967543	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.23
460.2256	460.2245	1	343212	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.41
461.2270	461.2271	1	35026	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	0.31
462.2307	462.2297	1	3280	C ₂₆ H ₂₇ N ₅ O ₃	(M+H) ⁺	-2.07

--- End Of Report ---


HRMS (ESI) analysis of **6**

3.7. N-methylpiperazine Derivative **7**





^{13}C -NMR spectrum of **7** (125.75 MHz, CDCl_3)





Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
456.2037	456.2030	1	4740963	C ₂₆ H ₂₅ N ₅ O ₃	(M+H) ⁺	-1.53
457.2068	457.2060	1	1456381	C ₂₆ H ₂₅ N ₅ O ₃	(M+H) ⁺	-1.7
458.2098	458.2088	1	256610	C ₂₆ H ₂₅ N ₅ O ₃	(M+H) ⁺	-2.24
459.2124	459.2115	1	30908	C ₂₆ H ₂₅ N ₅ O ₃	(M+H) ⁺	-1.96
460.2212	460.2141	1	4184	C ₂₆ H ₂₅ N ₅ O ₃	(M+H) ⁺	-15.5


--- End Of Report ---

HRMS (ESI) analysis of **7**


3.8. Dimethylethylenediamine Derivative **8**




HPLC trace of **8** monitored at 240 nm



^1H -NMR spectrum of **8** (500 MHz, CDCl_3)



^{13}C -NMR spectrum of **8** (125.75 MHz, CDCl_3)



MS Spectrum Peak List


Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
444.2035	444.2030	1	7473284	C ₂₅ H ₂₅ N ₅ O ₃	(M+H) ⁺	-0.99
445.2065	445.2060	1	2277215	C ₂₅ H ₂₅ N ₅ O ₃	(M+H) ⁺	-1.06
446.2094	446.2088	1	392031	C ₂₅ H ₂₅ N ₅ O ₃	(M+H) ⁺	-1.44
447.2116	447.2114	1	40285	C ₂₅ H ₂₅ N ₅ O ₃	(M+H) ⁺	-0.41


--- End Of Report ---

HRMS (ESI) analysis of **8**


N#CCNC(=O)c1ccc(cc1)n2nc(c3ccccc3O)n(c4ccccc4O)n2

9





^{13}C -NMR spectrum of **9** (125.75 MHz, $\text{DMSO}-d_6$)





MS Spectrum Peak List

Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
416.1728	416.1717	1	384495	C ₂₃ H ₂₁ NO ₃	(M+H) ⁺	-2.6
417.1753	417.1747	1	98604	C ₂₃ H ₂₁ NO ₃	(M+H) ⁺	-1.56
418.1783	418.1774	1	14843	C ₂₃ H ₂₁ NO ₃	(M+H) ⁺	-2.24
419.1857	419.1800	1	2215	C ₂₃ H ₂₁ NO ₃	(M+H) ⁺	-13.8
420.1409	420.1825	1	450	C ₂₃ H ₂₁ NO ₃	(M+H) ⁺	99.07


--- End Of Report ---

HRMS (ESI) analysis of **9**


3.10. O-Methylated Dimethylethylenediamine Derivative **10**




HPLC trace of **10** monitored at 240 nm



^1H -NMR spectrum of **10** (500 MHz, CDCl_3)



^{13}C -NMR spectrum of **10** (125.75 MHz, CDCl_3)




Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Tgt Mass Error (ppm)
236.6213			506046			
472.2348	472.2343	1	412045	C ₂₇ H ₂₉ N ₅ O ₃	(M+H) ⁺	-0.97
473.2374	473.2373	1	128379	C ₂₇ H ₂₉ N ₅ O ₃	(M+H) ⁺	-0.04
474.2393	474.2401	1	22506	C ₂₇ H ₂₉ N ₅ O ₃	(M+H) ⁺	1.8
475.2400	475.2428	1	2657	C ₂₇ H ₂₉ N ₅ O ₃	(M+H) ⁺	5.95
476.2758	476.2455	1	429	C ₂₇ H ₂₉ N ₅ O ₃	(M+H) ⁺	-63.75


--- End Of Report ---

HRMS (ESI) analysis of **10**


3.11. Oxazinone Intermediate A




Oxazinone Intermediate A



¹H-NMR spectrum of Intermediate A (400 MHz, CDCl₃)



^{13}C -NMR spectrum of Intermediate A (100.6 MHz, CDCl_3)




Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Ygt Mass Error (ppm)
240.0658	240.0655	1	581677	C ₁₄ H ₉ NO ₃	(M+H) ⁺	-1.24
241.0688	241.0688	1	88067	C ₁₄ H ₉ NO ₃	(M+H) ⁺	-0.37
242.0718	242.0712	1	11116	C ₁₄ H ₉ NO ₃	(M+H) ⁺	-2.31
243.0168	243.0738	1	502	C ₁₄ H ₉ NO ₃	(M+H) ⁺	234.28


--- End Of Report ---

HRMS (ESI) analysis of Intermediate A


3.12. *N*-boc-ethylenediamine Intermediate **B**




N-boc-ethylenediamine Intermediate **B**




^1H -NMR spectrum of Intermediate **B** (400 MHz, CDCl_3)



^1H -NMR spectrum of Intermediate **B** (500 MHz, $\text{DMSO}-d_6$)





¹³C-NMR spectrum of Intermediate B (125.75 MHz, DMSO-*d*₆)




HRMS (ESI) analysis of Intermediate B


3.13. Trimethylated Intermediate C



¹H-NMR spectrum of Intermediate **C** (500 MHz, CDCl₃)




¹³C-NMR spectrum of Intermediate C (125.75 MHz, CDCl₃)




HRMS (ESI) analysis of Intermediate C


3.14. Hydrolyzed Intermediate **D**




Hydrolyzed Intermediate **D**



¹H-NMR spectrum of Intermediate **D** (500 MHz, DMSO-*d*₆)



¹³C-NMR spectrum of Intermediate **D** (125.75 MHz, DMSO-*d*₆)



Obs. m/z	Calc. m/z	Charge	Abundance	Formula	Ion Species	Ygt Mass Error (ppm)
402.1450	402.1448	1	1416644	C ₂₃ H ₁₉ N ₃ O ₄	(M+H) ⁺	-0.43
403.1484	403.1480	1	368951	C ₂₃ H ₁₉ N ₃ O ₄	(M+H) ⁺	-1.22
404.1503	404.1507	1	57094	C ₂₃ H ₁₉ N ₃ O ₄	(M+H) ⁺	1.03
405.1543	405.1533	1	6626	C ₂₃ H ₁₉ N ₃ O ₄	(M+H) ⁺	-2.58
406.1635	406.1559	1	1226	C ₂₃ H ₁₉ N ₃ O ₄	(M+H) ⁺	-18.83




--- End Of Report ---









HRMS (ESI) analysis of Intermediate **D**





4. Compound Stability Test and HPLC Retention Times

Procedure:

10 mM stock solutions in DMSO were prepared for compounds **1-9**. Into a glass vial was added 1 mL of a PBS buffer solution and 20 μ L of compound from the appropriate stock solution resulting in a final concentration of 200 μ M for each compound, respectively. Vials were kept in a warm water bath at 37°C for 72 h. Aliquots of each compound were taken after 0 h, 24 h and 72 h, respectively, and analyzed via HPLC with UV detection at 240 nm. Chromatograms are shown with an off-set of 0.5 min along the abscissa and 0.1 along the ordinate to facilitate intercomparisons of the 3 evaluated time points.







5. LogD_{7.2} and logD_{4.5} Determination

500 mL aliquots of purified octanol and aqueous phase were thoroughly mixed in a 2 L separatory funnel to saturate the two phases. For compounds **1-9**, 20 µM standard solutions were prepared in aqueous phase-saturated octanol, respectively. 5 mL standard solutions containing the compound in question were then pipetted into 15 mL centrifuge tubes, and a 5 mL aliquot of the octanol-saturated aqueous phase was added. The resulting samples were shaken for 10 min and allowed to sit overnight for 18 hours. The samples were then centrifuged for 30 min (3000 g, 20° C) and aliquots of the octanol phase were withdrawn and analyzed via UV-vis spectroscopy. Experiments were conducted in triplicate. The concentrations of the deferasirox derivatives in the octanol phase were quantified using to their absorbance at 300 nm. logD was defined as:

$$\log D = \log \left(\frac{A_0}{A_0 - A_S} \right)$$

where A_0 = absorbance of 20 µM compound in aqueous phase- saturated octanol
 A_S = absorbance of compound in octanol phase after shaking with aqueous phase

Aqueous phases:

pH 7.2 (logD_{7.2}): PBS buffer solution

pH 4.5 (logD_{4.5}): 0.1 M AcOH/AcONa buffer

LogD values >3 could not be determined via this method due to the sensitivity limit of the UV-vis instrument that did not allow to distinguish absorbance differences below 0.001.



Compound	Log D _{7.2}	Log D _{4.5}	HPLC Retention time	
1	1.16 ± 0.02	>3	9.49 min	 1 =  2 =  3 =  4 =  5 =  6 =  7 =  8 =  9 = 
2	>3	>3	10.16 min	
3	>3	n.d.	8.60 min	
4	>3	n.d.	9.02 min	
5	2.56 ± 0.33	n.d.	8.75 min	
6	1.02 ± 0.03	n.d.	7.26 min	
7	2.07 ± 0.07	1.41 ± 0.01	6.94 min	
8	2.15 ± 0.07	1.35 ± 0.03	7.20 min	
9	1.18 ± 0.02	1.24 ± 0.03	7.25 min	

Table S1: logD values for **1-9** at pH = 7.2 and pH = 4.5, respectively. For comparison, HPLC retention times on a C18 reverse phase column using methanol and acidified water as solvent system are included. n.d. = not determined.

6. Cell Viability Studies

MTT and CV assay in HCT-116, L929, A549 cell lines:

The highest concentration of the compound: 250 μM ; a 3-fold serial dilution was employed.

MTT assays in A549 after pre-incubation of compounds with HSA:

The highest concentration of compound and HSA, respectively: 100 μM (1:1); a 2-fold serial dilution was employed.




Figure S1: a) Proliferation profiles in A549 cells after 72 h of exposure to varying concentrations of 1-9 with the highest concentration = 250 μM . b) Corresponding IC_{50} and HS values derived from the proliferation profiles.




Figure S2: a) Proliferation profiles in A549 cells after 24 h of exposure to varying concentrations of 1-9 with the highest concentration = 250 μM . b) Corresponding IC_{50} and HS values derived from the proliferation profiles




Figure S3: Proliferation profiles of A549 cells exposed to varying concentrations of **1** and **8** in the presence and absence of 50 μM supplemental FeCl_3 , respectively. exposure time was 72 h and highest concentration = 250 μM .




Figure S4: Proliferation profiles of HCT116 colon cancer cells (left) and L929 murine fibroblast cells (right) exposed to varying concentrations of **1**, **2** and **8**, respectively. Exposure time was 72 h and highest concentration = 250 μM .




Figure S5: Proliferation profiles of A549 cells exposed to varying concentrations of **1**, **2** and **8**, respectively, in the presence of 1 equivalent of HSA. Exposure time was 72 h and highest concentration = 100 μM .

Comp.	A549	HCT 116	L929	A549 + HSA
1	$8.5 \pm 2.0 \mu\text{M}$	$3.5 \pm 0.3 \mu\text{M}$	$11.6 \pm 1.9 \mu\text{M}$	$7.4 \pm 0.6 \mu\text{M}$
2	$2.5 \pm 0.7 \mu\text{M}$	$1.0 \pm 0.1 \mu\text{M}$	$1.3 \pm 0.2 \mu\text{M}$	$0.9 \pm 0.1 \mu\text{M}$
8	$3.7 \pm 0.3 \mu\text{M}$	$2.7 \pm 0.3 \mu\text{M}$	$2.8 \pm 0.3 \mu\text{M}$	$1.7 \pm 0.2 \mu\text{M}$

Table S2: IC_{50} values of **1**, **2** and **8** in A549, HCT116 and L929 cells after 72 h incubation as determined via MTT assay. Pre-incubation with HSA resulted in lower IC_{50} values (greater potency) for **2** and **8** in A549 cells under otherwise identical conditions.




Figure S6: a) Proliferation profiles of A549 cells exposed to varying concentrations of **2**, **5** and **8**, respectively, as determined by crystal violet (CV) staining. Exposure time was 72 h and the highest concentration was 250 μM. b) IC₅₀ values using CV staining. The corresponding values derived from MTT staining are shown for convenience.

7. Binding of 1, 2 and 8 to HSA as Determined via Stern-Volmer Plot

To a solution of 5 μM HSA in deionized water was added incremental amounts of each respective chelator from a 1 mM stock solution in DMSO. Emission profiles were collected with excitation at 290 nm; excitation and emission slit width was 5 nm, respectively. From the fluorescence intensity at 360 nm, Stern-Volmer plots were constructed in accord with the Stern-Volmer equation:

$$\frac{F_0}{F_x} - 1 = K_{SV}[Q] = k_q\tau_0[Q]$$

With F_0 , F_x = fluorescence intensity at 360 nm in the absence (F_0) and presence (F_x) of quencher Q ,

K_{SV} = Stern–Volmer quenching constant,

k_q = the bimolecular rate constant of the quenching reaction, and

τ_0 = the average fluorescent lifetime ($\tau_0 = 5 \times 10^{-9}\text{s}$ = fluorescent lifetime of the relevant tryptophan moieties in HSA)^{4–6}

Modification of the Stern–Volmer equation allowed us to estimate n , the number of equivalents of quencher that bind to HSA, and K_a , the binding constant between the quencher and HSA,^{4–6} as follows:

$$\log\left(\frac{F_0}{F_x} - 1\right) = n * \log[Q] + \log K_a$$




Figure S7: a) Emission profiles of 5 μM HSA titrated with 1, b) Stern-Volmer plot: F_0 , F_x = fluorescence intensity at 360 nm (emission of HSA) in the absence (F_0) and presence (F_x) of quencher 1, c) double logarithm plot




Figure S8: a) Emission profiles of 5 μM HSA titrated with **2**, b) Stern-Volmer plot: F_0 , F_x = fluorescence intensity at 360 nm (emission of HSA) in the absence (F_0) and presence (F_x) of quencher **2**, c) double logarithm plot




Figure S9: a) Emission profiles of 5 μM HSA titrated with **8**, b) Stern-Volmer plot: F_0 , F_x = fluorescence intensity at 360 nm (emission of HSA) in the absence (F_0) and presence (F_x) of quencher **8**, c) double logarithm plot

Compound	$K_{SV} (\text{M}^{-1})$	$k_q (\text{M}^{-1} \text{s}^{-1})$	n	$K_a (\text{M}^{-1})$
1	$3.93 \cdot 10^4$	$7.86 \cdot 10^{12}$	0.99	$3.49 \cdot 10^4$
2	$3.23 \cdot 10^4$	$6.46 \cdot 10^{12}$	1.06	$7.38 \cdot 10^4$
8	$3.11 \cdot 10^4$	$6.22 \cdot 10^{12}$	1.09	$7.94 \cdot 10^4$

Table S3: Summary of Stern-Volmer and double logarithm plot results. k_q for all evaluated compounds exceeded the diffusion limit of $\approx 6 \cdot 10^9 \text{ M}^{-1} \text{ s}^{-1}$ and thus involvement of static quenching through binding to HSA is invoked.^{4,7} For each compound, a 1:1 binding stoichiometry with HSA was inferred from the slope n of the double logarithm plot, which was used to generate the corresponding association constant, K_a , from the intercept of the plot.

8. UV-vis and Fluorescence Spectroscopy




Figure S10: Spectra of **1**, **2**, **3** and **4** at 50 μM in PBS (pH = 7.2) containing <0.5% DMSO: A) UV-vis absorbance spectra B) Fluorescence emission spectra with excitation at 360 nm and a slit width of 10 nm (5 nm for **2**)




Figure S11: Spectra of **1**, **5** and **6** at 50 μM in PBS (pH = 7.2) containing <0.5% DMSO: A) UV-vis absorbance spectra B) Fluorescence emission spectra with excitation at 360 nm and a slit width of 10 nm (5 nm for **5**)




Figure S12: Spectra of **1**, **7**, **8** and **9** at 50 μM in PBS (pH = 7.2) containing <0.5% DMSO: A) UV-vis absorbance spectra B) Fluorescence emission spectra with excitation at 360 nm and a slit width of 10 nm

9. Cell Imaging




Figure S13: a) Proliferation profiles of HeLa cells 24 h after exposure to varying concentrations of **1**, **2** and **8**, respectively, as determined by MTT assay. Highest concentration = 80 μM; a 2-fold serial dilution was employed.

b) Confocal microscopy imaging of **2** and **8** (20 μM) in HeLa cells. Colocalization was observed between **8** and Lysotracker® red. Blue channel: Ex/Em = 405/ 440–480 nm. Red channel: Ex/Em = 559/ 580–620 nm.




Figure S14: Confocal microscopy imaging of A549 cells stained with Lysotracker® red (100 nM) and H2DCFDA dye (2 μ M) after treatment with **8** (5 μ M or 20 μ M, respectively), “Compound 1” developed in our lab, an established ROS inducer⁷ (2.5 μ M, positive control), or no prior treatment (negative control). ROS production was not observed for **8**. Green channel: Ex/Em = 488/500-550 nm. Red channel: Ex/Em = 561/573-639 nm.




Figure S15: Confocal microscopy imaging of **5** (20 μ M) in A549 cells. Colocalization was not observed between **5** and Mitotracker® red. Blue channel: Ex/Em = 405/ 500-550 nm. Red channel: Ex/Em = 561/ 573-639 nm.

10. References

- 1 S. Sen, S. Hufnagel, E. Y. Maier, I. Aguilar, J. Selvakumar, J. E. Devore, V. M. Lynch, K. Arumugam, Z. Cui, J. L. Sessler and J. F. Arambula, *J. Am. Chem. Soc.*, 2020, **142**, 20536–20541.
- 2 S. Steinhäuser, U. Heinz, M. Bartholomä, T. Weyhermüller, H. Nick and K. Hegetschweiler, *Eur. J. Inorg. Chem.*, 2004, **2004**, 4177–4192.
- 3 A. Khalafi-Nezhad, B. Mokhtari and M. N. S. Rad, *Tetrahedron Lett.*, 2003, **44**, 7325–7328.
- 4 S. Sen, M. W. Perrin, A. C. Sedgwick, E. Y. Dunskey, V. M. Lynch, X. P. He, J. L. Sessler and J. F. Arambula, *Chem. Commun.*, 2020, **56**, 7877–7880.
- 5 S. Nusrat, M. K. Siddiqi, M. Zaman, N. Zaidi, M. R. Ajmal, P. Alam, A. Qadeer, A. S. Abdelhameed and R. H. Khan, *PLoS One*, 2016, **11**, 1–20.
- 6 J. R. Lakowicz, in *Principles of Fluorescence Spectroscopy*, 2006, pp. 97–156.
- 7 J. G. Calvert and J. N. Pitts, in *Photochemistry*, John Wiley & Sons, Inc., 1966, pp. 626–627.